Home » Stocks » PHIO

Phio Pharmaceuticals Corp. (PHIO)

Stock Price: $2.91 USD -0.08 (-2.68%)
Updated Jan 15, 2021 4:00 PM EST - Market closed
After-hours: $2.85 -0.06 (-2.06%) Jan 15, 7:09 PM
Market Cap 16.82M
Revenue (ttm) n/a
Net Income (ttm) -8.99M
Shares Out 5.78M
EPS (ttm) -2.74
PE Ratio n/a
Forward PE 1.04
Dividend n/a
Dividend Yield n/a
Trading Day January 15
Last Price $2.91
Previous Close $2.99
Change ($) -0.08
Change (%) -2.68%
Day's Open 3.03
Day's Range 2.87 - 3.09
Day's Volume 223,816
52-Week Range 1.68 - 9.77

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
PRNewsWire - 1 week ago

MARLBOROUGH, Mass., Jan. 4, 2021 /PRNewswire/ -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a biotechnology company developing the next generation of immuno-oncology therapeutics based on its ...

PRNewsWire - 1 month ago

MARLBOROUGH, Mass., Nov. 19, 2020 /PRNewswire/ -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a biotechnology company developing the next generation of immuno-oncology therapeutics based on its...

PRNewsWire - 2 months ago

MARLBOROUGH, Mass., Nov. 10, 2020 /PRNewswire/ -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a biotechnology company developing the next generation of immuno-oncology therapeutics based on its...

PRNewsWire - 2 months ago

MARLBOROUGH, Mass., Nov. 9, 2020 /PRNewswire/ -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a biotechnology company developing the next generation of immuno-oncology therapeutics based on its ...

PRNewsWire - 2 months ago

MARLBOROUGH, Mass., Oct. 26, 2020 /PRNewswire/ -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a biotechnology company developing the next generation of immuno-oncology therapeutics based on its...

PRNewsWire - 4 months ago

MARLBOROUGH, Mass., Sept. 9, 2020 /PRNewswire/ -- Phio Pharmaceuticals Corp.

PRNewsWire - 5 months ago

MARLBOROUGH, Mass., Aug. 12, 2020 /PRNewswire/ -- Phio Pharmaceuticals Corp.

24/7 Wall Street - 7 months ago

Phio Pharmaceuticals Corp. (NASDAQ: PHIO) shares more than doubled on Friday after the firm announced positive data from its cancer study at the American Society of Clinical Oncology (ASCO) 20...

PRNewsWire - 8 months ago

MARLBOROUGH, Mass., May 14, 2020 /PRNewswire/ -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a biotechnology company developing the next generation of immuno-oncology therapeutics based on its ...

About PHIO

Phio Pharmaceuticals, a biotechnology company, develops immuno-oncology therapeutics in the United States. It offers INTASYL therapeutic platform focuses on silencing tumor-induced suppression of the immune system. The company develops PH-762 which targets the checkpoint protein PD-1 on immune cells for used in adoptive cell transfer (ACT); PH-804 that targets the suppressive immune receptor TIGIT, which is a checkpoint protein present on T cells and natural killer cells for used in ACT; and PH-790 which targets PD-L1 protein that keeps immune ... [Read more...]

Industry
Biotechnology
CEO
Gerrit Dispersyn
Employees
11
Stock Exchange
NASDAQ
Ticker Symbol
PHIO
Full Company Profile

Financial Performance

In 2019, PHIO's revenue was $21,000, a decrease of -84.78% compared to the previous year's $138,000. Losses were -$8.91 million, 21.0% more than in 2018.

Financial Statements

Analyst Forecasts

According to one analyst, the rating for PHIO stock is "Buy" and the 12-month stock price forecast is 4.00.

Price Target
$4.00
Analyst Consensus: Buy